← All trials
NCT06434753
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 2, 2022
- Primary completion
- Mar 2, 2026
- Completion date
- Mar 2, 2026
- First posted
- May 30, 2024
- Last posted
- Jun 4, 2024
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universidad Autonoma de BarcelonaLead sponsor
- University of CantabriaCollaborator
- Hospital General Universitario Gregorio MarañonCollaborator
- Badalona Hospital Germans Trias i PujolCollaborator
- University of BarcelonaCollaborator
- Universidad Autonoma de BarcelonaCollaborator
- University of BarcelonaCollaborator
- Universidad Autonoma de BarcelonaCollaborator
- Hospital Universitario Central de AsturiasCollaborator
- University of ZaragozaCollaborator
- Universidad Autonoma de MadridCollaborator
- Institut d'Investigació Biomèdica de Girona Dr. Josep TruetaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.